A bibliometric analysis of myocardial ischemia/reperfusion injury from 2000 to 2023

BackgroundMyocardial ischemia/reperfusion injury (MIRI) refers to the more severe damage that occurs in the previously ischemic myocardium after a short-term interruption of myocardial blood supply followed by restoration of blood flow within a certain period of time. MIRI has become a major challenge affecting the therapeutic efficacy of cardiovascular surgery.MethodsA scientific literature search on MIRI-related papers published from 2000 to 2023 in the Web of Science Core Collection database was conducted. VOSviewer was used for bibliometric analysis to understand the scientific development and research hotspots in this field.ResultsA total of 5,595 papers from 81 countries/regions, 3,840 research institutions, and 26,202 authors were included. China published the most papers, but the United States had the most significant influence. Harvard University was the leading research institution, and influential authors included Lefer David J., Hausenloy Derek J., Yellon Derek M., and others. All keywords can be divided into four different directions: risk factors, poor prognosis, mechanisms and cardioprotection.ConclusionResearch on MIRI is flourishing. It is necessary to conduct an in-depth investigation of the interaction between different mechanisms and multi-target therapy will be the focus and hotspot of MIRI research in the future

Effects of the pyrE deletion mutant from Bacillus thuringiensis on gut microbiota and immune response of Spodoptera exigua

The gut microbiota is essential for the growth and development of insects, and the intestinal immune system plays a critical role in regulating the homeostasis of intestinal microorganisms and their interactions with pathogenic bacteria. Infection with Bacillus thuringiensis (Bt) can disrupt the gut microbiota of insects, but the regulatory factors governing the interaction between Bt and gut bacteria are not well understood. Uracil secreted by exogenous pathogenic bacteria can activate DUOX-mediated reactive oxygen species (ROS) production, which helps maintain intestinal microbial homeostasis and immune balance. To elucidate the regulatory genes involved in the interaction between Bt and gut microbiota, we investigate the effects of uracil derived from Bt on gut microbiota, and host immunity using a uracil deficient Bt strain (Bt GS57△pyrE) obtained by homologous recombination. We analyze the biological characteristics of the uracil deficient strain and found that the deletion of uracil in Bt GS57 strain changed the diversity of gut bacteria in Spodoptera exigua, as investigated using Illumina HiSeq sequencing. Furthermore, qRT-PCR analysis showed that compared with Bt GS57 (control), the expression of the SeDuox gene and the level of ROS were significantly decreased after feeding with Bt GS57△pyrE. Adding uracil to Bt GS57△pyrE restored the expression level of DUOX and ROS to a higher level. Additionally, we observed that PGRP-SA, attacin, defensin and ceropin genes were significant different in the midgut of S. exigua infected by Bt GS57 and Bt GS57△pyrE, with a trend of increasing first and then decreasing. These results suggest that uracil regulates and activates the DUOX-ROS system, affects the expression of antimicrobial peptide genes, and disturb intestinal microbial homeostasis. We preliminarily speculate that uracil is a key factor in the interaction between Bt and gut microbiota, and these findings provide a theoretical basis for clarifying the interaction between Bt, host, and intestinal microorganisms, as well as for gaining new insights into the insecticidal mechanism of B. thuringiensis in insects

CUDAS: Distortion-aware saliency benchmark

Visual saliency prediction remains an academic challenge due to the diversity and complexity of natural scenes as well as the scarcity of eye movement data on where people look in images. In many practical applications, digital images are inevitably subject to distortions, such as those caused by acquisition, editing, compression or transmission. A great deal of attention has been paid to predicting the saliency of distortion-free pristine images, but little attention has been given to understanding the impact of visual distortions on saliency prediction. In this paper, we first present the CUDAS database - a new distortion-aware saliency benchmark, where eye-tracking data was collected for 60 pristine images and their corresponding 540 distorted formats. We then conduct a statistical evaluation to reveal the behaviour of state-of-the-art saliency prediction models on distorted images and provide insights on building an effective model for distortion-aware saliency prediction. The new database is made publicly available to the research community

Effect of arotinolol on chronic heart failure: A systematic review and meta-analysis of randomized controlled trials

BackgroundHeart failure is the end stage of all cardiovascular diseases, which brings a heavy burden to the global health network. Arotinolol, as a new type of β Receptor blocker, has a good antihypertensive effect. Many clinical trials have observed the clinical efficacy of arotinolol in the treatment of essential hypertension. However, so far, there has been no systematic evaluation on the efficacy and safety of arotinolol in the treatment of chronic heart failure.ObjectiveThe purpose of this review was to systematically evaluate the clinical efficacy of arotinolol in patients with chronic heart failure.MethodsRandomized controlled trials (RCTs) of arotinolol in the treatment of chronic heart failure were retrieved from seven databases according to the Cochrane manual, including CNKI (China National Knowledge Infrastructure), Wan fang database, VIP database, PubMed, Sinomed, EMBASE, and the Cochrane Library databases. The main outcomes were the effective rate, left ventricular ejection fraction (LVEF), blood pressure, heart rate, cardiac index, stroke volume (SV), brain natriuretic peptide (BNP), hypersensitive C-reactive protein (Hs-CRP), left ventricular end diastolic volume (LVEDV), left ventricular end diastolic diameter (LVEDD), and adverse events (AEs).ResultsA total of 17 trials met the qualification criteria, which included 1,717 patients with heart failure. Most trials had uncertain risks in terms of random sequence generation, allocation hiding, patient loss, and result evaluation. Meta analysis showed that arotinolol significantly improved the treatment efficiency of patients with heart failure (standardized mean difference (SMD) = 4.07, 95% confidence interval (CI) [2.89, 5.72], p = 0.00, I2 = 0), LVEF (SMD = 1.59, 95% CI [0.99, 2.19], p = 0.000 0, I2 = 95.8%), cardiac index (SMD = 0.32, 95% CI [0.11, 0.53], p = 0.03), I2 = 0), SV (SMD = 2.00, 95% CI [1.57, 2.34], p = 0.000, I2 = 64.2%), lower BNP (SMD = −0.804, 95% CI [−0.97, −0.64], p = 0.000, I2 = 94.4%), and LVEDV (SMD = −0.25, 95% CI [−0.45, −0.05], p = 0.015, I2 = 0). There was no statistical significance for blood pressure (SMDsystolic pressure = −0.09, 95% CI [−0.69, 0.51], p = 0.775, I2systolic pressure = 90.2%; SMDdiastolic pressure = −0.16, 95% CI [−0.79, 0.48], P = 0.632, I2diastolic pressure = 91.2%), heart rate (SMD = −0.12, 95% CI [−1.00, 0.75], P = 0.787, I2 = 96.1%), Hs-CRP (SMD = −1.52, 95% CI [−3.43, 0.40], P = 0.121, I2 = 98.3%), and LVEDD (SMD = −0.07, 95% CI [−0.90, 0.76], P = 0.870, I2 = 96.5%).ConclusionArotinolol can safely and effectively improve the effective rate of patients with chronic heart failure, increase LVEF, increase CI and SV, and reduce BNP and LVEDV. However, because of the low overall quality of the included randomized controlled trials, these findings need to be considered carefully. More high-quality randomized controlled trials are needed for further verification, to provide a more scientific basis for the safety and effectiveness of arotinolol in the clinical treatment of heart failure.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=371214], identifier [CRD:420223371214]

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Iron Carbide Nanoparticles Embedded in Edge-Rich, N and F Codoped Graphene/Carbon Nanotubes Hybrid for Oxygen Electrocatalysis

Rational design of cost-effective and efficient bifunctional oxygen electrocatalysts for sluggish oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) is urgently desired for rechargeable metal–air batteries and regenerative fuel cells. Here, the Fe3C nanoparticles encapsulated in N and F codoped and simultaneously etched graphene/CNTs architecture catalyst (Fe3C@N-F-GCNTs) was synthesized by a simple yet cost-effective strategy. The as-prepared Fe3C@N-F-GCNTs exhibited excellent ORR and OER performances, with the ORR half-wave potential positive than that of Pt/C by 14 mV, and the OER overpotential lowered to 432 mV at the current density of 10 mA·cm−2. In addition, the ΔE value (oxygen electrode activity parameter) increased to 0.827 V, which is comparable to the performance of the best nonprecious metal catalysts reported to date. When it was applied in a Zn–air battery as a cathode, it achieved a peak power density of 130 mW·cm−2, exhibiting the potential for large-scale applications

Iron Carbide Nanoparticles Embedded in Edge-Rich, N and F Codoped Graphene/Carbon Nanotubes Hybrid for Oxygen Electrocatalysis

Rational design of cost-effective and efficient bifunctional oxygen electrocatalysts for sluggish oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) is urgently desired for rechargeable metal–air batteries and regenerative fuel cells. Here, the Fe3C nanoparticles encapsulated in N and F codoped and simultaneously etched graphene/CNTs architecture catalyst (Fe3C@N-F-GCNTs) was synthesized by a simple yet cost-effective strategy. The as-prepared Fe3C@N-F-GCNTs exhibited excellent ORR and OER performances, with the ORR half-wave potential positive than that of Pt/C by 14 mV, and the OER overpotential lowered to 432 mV at the current density of 10 mA·cm−2. In addition, the ΔE value (oxygen electrode activity parameter) increased to 0.827 V, which is comparable to the performance of the best nonprecious metal catalysts reported to date. When it was applied in a Zn–air battery as a cathode, it achieved a peak power density of 130 mW·cm−2, exhibiting the potential for large-scale applications

Functionalized MoS2-nanoparticles for transdermal drug delivery of atenolol

Molybdenum disulfide (MoS2) has excellent photothermal conversion abilities, an ultra-high specific surface area, and has been extensively explored for use in biomedicine. However, the high toxicity associated with MoS2 has limited its biological applications for in vivo photothermal therapy and drug delivery systems. Herein, we have developed cationic hydroxyethyl cellulose (JR400) surface-modified MoS2 nanoparticles (NPs) that are responsive to near-infrared (NIR) laser irradiation as a transdermal drug delivery system (TDDS). Herein, we confirmed the preparation of hexagonal phase MoS2 with robust surface modification with JR400. The flower-like morphology of the NPs had an average diameter of 355 ± 69.3 nm limiting the absorption of the NPs through the stratum corneum. With the ability to efficiently load 90.4 ± 0.3% of the model drug atenolol (ATE), where 1 g of JR400-MoS2 NPs was able to load 3.6 g ATE, we assayed the controlled release capacity in vitro skin penetration studies. These JR400-MoS2 NPs showed further enhancement under NIR stimulation, with a 2.3-fold increase in ATE skin penetration. Furthermore, we verified in vivo that these JR400-MoS2 NPs do not cause skin irritation suggesting that they are promising new TDDS candidates for small molecule drugs